AP05292PU-N SET / I2PP2A antibody

See related secondary antibodies

Search for all "SET / I2PP2A"

0.1 mg / €370.00
Please visit the country specific website of Acris Antibodies or contact your local Distributor to buy this product.

Quick Overview

Rabbit anti Human SET / I2PP2A


Product Description for SET / I2PP2A

Rabbit anti Human SET / I2PP2A.
Presentation: Aff - Purified
Product is tested for Western blot / Immunoblot.

Properties for SET / I2PP2A

Product Category Primary Antibodies
Quantity 0.1 mg
Synonyms I-2PP2A, IGAAD, Inhibitor of granzyme A-activated DNase, PHAPII, Phosphatase 2A inhibitor I2PP2A, TAF-I, Template-activating factor I
Presentation Aff - Purified
Reactivity Hu
Applications WB
Clonality Polyclonal
Host Rabbit
Isotype IgG
Shipping to Worldwide
PDF datasheet View Datasheet
Manufacturer Acris Antibodies GmbH
Material safety datasheet MSDS for Polyclonal Antibodies (de)

Datasheet Extract

Swiss Prot Num:
Synthetic peptide derived from the human SET protein
Control peptide AP05292CP-N
Application Western blot (1:400 dilution).
Background Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression arefound in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.
Concentration Lot specific
General Readings
  1. von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene. Mol Cell Biol. 1992 Aug;12(8):3346-55. PubMed PMID: 1630450. (Free PMC Article available)
  2. Vaesen M, Barnikol-Watanabe S, Götz H, Awni LA, Cole T, Zimmermann B, et al. Purification and characterization of two putative HLA class II associated proteins: PHAPI and PHAPII. Biol Chem Hoppe Seyler. 1994 Feb;375(2):113-26. PubMed PMID: 8192856.
  3. Nagata K, Kawase H, Handa H, Yano K, Yamasaki M, Ishimi Y, et al. Replication factor encoded by a putative oncogene, set, associated with myeloid leukemogenesis. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4279-83. PubMed PMID: 7753797. (Free PMC Article available)
  4. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem. 1996 May 10;271(19):11059-62. PubMed PMID: 8626647.
  5. Tsujio I., Zaidi T., Xu J., Kotula L., Grundke-Iqbal I., Iqbal K.; "Inhibitors of protein phosphatase-2A from human brain: structures, immunocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated Tau."; Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
  6. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, et al. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. PubMed PMID: 15489334. (Free PMC Article available, 2 images available)
  7. Adachi Y, Pavlakis GN, Copeland TD. Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem. 1994 Jan 21;269(3):2258-62. PubMed PMID: 8294483.
  8. Wang L.C., Chen Y.; "A relative factor in human rectum carcinoma."; Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases.
  9. Carlson SG, Eng E, Kim EG, Perlman EJ, Copeland TD, Ballermann BJ. Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor. J Am Soc Nephrol. 1998 Oct;9(10):1873-80. PubMed PMID: 9773788.
  10. Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell. 2001 Jan 12;104(1):119-30. PubMed PMID: 11163245.
  11. Minakuchi M, Kakazu N, Gorrin-Rivas MJ, Abe T, Copeland TD, Ueda K, et al. Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET. Eur J Biochem. 2001 Mar;268(5):1340-51. PubMed PMID: 11231286.
  12. Fan Z, Beresford PJ, Zhang D, Lieberman J. HMG2 interacts with the nucleosome assembly protein SET and is a target of the cytotoxic T-lymphocyte protease granzyme A. Mol Cell Biol. 2002 Apr;22(8):2810-20. PubMed PMID: 11909973. (Free PMC Article available, 7 images available)
  13. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell. 2003 Mar 7;112(5):659-72. PubMed PMID: 12628186.
  14. Fan Z., Beresford P.J., Oh D.Y., Zhang D., Lieberman J.; Cell 115:241-241(2003).
  15. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006 Nov 3;127(3):635-48. PubMed PMID: 17081983.
  16. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell. 2006 Aug;23(4):607-18. PubMed PMID: 16916647.
  17. Molina H, Horn DM, Tang N, Mathivanan S, Pandey A. Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2199-204. Epub 2007 Feb 7. PubMed PMID: 17287340. (Free PMC Article available, 5 images available)
Storage Store the product (in aliquots) at -20 °C to -70 °C. Can be shipped at 2 - 8 °C.
Avoid repeated freezing and thawing.
Shelf life: One year from despatch.
Affinity chromatography
Buffer System:
Phosphate buffered saline with 0.08% sodium azide
Aff - Purified
Liquid Ig fraction
Aff - Purified
This antibody detects I2PP2A / SET, widely expressed. Low levels in quiescent cells during serum starvation, contact inhibition or differentiation. Highly expressed in Wilms' tumor.
Gene ID 6418

Accessory Products

Proteins and/or Positive Controls

Proteins for SET / I2PP2A (6 products)

Catalog No. Species Pres. Purity   Source  

SET (1-290, His-tag)

SET Human Purified > 90 % by SDS - PAGE E. coli
0.5 mg / €730.00
  Acris Antibodies GmbH

SET (1-290, His-tag)

SET Human Purified > 90 % by SDS - PAGE E. coli
0.1 mg / €300.00
  Acris Antibodies GmbH


SET / I2PP2A Human 12.5% SDS-PAGE Stained with Coomassie Blue. in vitro transl.
  Abnova Taiwan Corp.


SET / I2PP2A Human 12.5% SDS-PAGE Stained with Coomassie Blue. in vitro transl.
  Abnova Taiwan Corp.

TSTD3 (1-97, His-tag)

TSTD3 Human Purified > 90 % by SDS - PAGE E. coli
0.5 mg / €940.00
  Acris Antibodies GmbH

TSTD3 (1-97, His-tag)

TSTD3 Human Purified > 90 % by SDS - PAGE E. coli
0.1 mg / €370.00
  Acris Antibodies GmbH

Positive controls for SET / I2PP2A (2 products)

Catalog No. Species Pres. Purity   Source  

SET Lysate

Western Blot: SET Lysate [NBL1-15867] - Western Blot experiments. 
Left-Control; Right -Over-expression Lysate for SET
  Novus Biologicals Inc.

TSTD3 overexpression lysate

TSTD3 overexpression lysate
0.1 mg / €295.00
  OriGene Technologies, Inc.
  • LinkedIn